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With the advent of highly active antiretroviral therapy in
1996, patients infected with HIV are now living longer
and dying from illnesses other than acquired immuno-
deficiency syndrome (AIDS). Liver disease due to
chronic hepatitis B and C is now a leading cause of
mortality among HIV-infected patients in the developed
world. For these patients, liver transplantation (OLT) is
the only therapeutic option and HIV infection alone is
not a contraindication. The current HIV selection cri-
teria for HIV-infected OLT candidates are as follows: 1)
ideally no history of opportunistic infections or HIV-
related cancer, although some treatable and preventable
opportunistic infections are not exclusion criteria; 2)
CD4 cell count >100 cells/mm
3;a n d ,3 )p l a s m aH I V
RNA viral load that is undetectable or can be sup-
pressed with antiretroviral treatment. Drug users must
abstain from heroin and cocaine, although patients can
be in a methadone programme. Accumulated experience
in North America and Europe in the last few years indi-
cates that five-year survival in liver recipients coinfected
with HIV and HCV is lower than that of HCV-monoin-
fected recipients, being the five-year survival of around
50%. Conversely, 3-5–year survival of non-HCV-HIV-
coinfected liver recipients is very good and it was similar
to that of HIV-negative patients. Pharmacokinetic (PK)
and pharmacodynamic interactions between NNRTI- or
protease-inhibitor based regimens and immunosuppres-
sors have been one of the most important problems in
the post-trasplant period, although with the new
NNRTI- and protease inhibitor-sparing raltegravir-based
regimens we can avoid them. Other problems in the
post-transplant period are the high rates of acute rejec-
tion, and the HCV re-infection in HIV-infected liver
recipients, that is the main cause of mortality. Better
anti-HCV management and therapy could improve the
long-term outcome of OLT recipients coinfected with
HIV and HCV.
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